Alcohol Abuse

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.

The FDA gave positive feedback to Adial Pharmaceuticals regarding its proposed in vitro bridging strategy for the phase 3 formulation of AD04.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

At the beginning of this year, US Surgeon General Vivek H. Murthy, MD, MBA, issued a health advisory warning about the link between alcohol use and the risk of cancer. Learn more about its implications for psychiatry here.

Check out the pipeline updates from January!

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

New positive results of a pharmacokinetics study of AD04 for alcohol use disorder confirms the near micro-dosing regimen planned for upcoming trials.

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

An observational cohort study found patients at less risk of hospitalization for alcohol use disorder when also being treated with a GLP-1 agonist anti-diabetic/obesity agent.

Check out new results of a pharmacokinetics study of AD04, an investigational therapeutic agent for the treatment of alcohol use disorder in patients with heavy drinking.

Enter your email to check out this complicated case!

In this CME article, learn how best to provide end-of-life care to patients with psychiatric disorders.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

Learn more about the latest research related to 9/11 trauma and other psychiatric comorbidities.

In this CME article, learn more about how to assess the impact of alcohol and cannabis use on anxiety treatment outcomes, recognizing potential adverse effects and interactions.

Social media is here to stay, and its use must be a consideration in the treatment of psychiatric conditions, particularly substance use disorder and alcohol use disorder.

What is new in research on alcohol use disorder?

Here are highlights from the week in Psychiatric Times.

The study aims to collect data to optimize the design of the treatment’s upcoming phase 3 clinical trial.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.

Which is the best recommendation for the treatment of alcohol use disorder?

Take a look back at our recent coverage relating to our April content theme.

What is new in research on alcohol use disorder?

In honor of this year’s National Alcohol Screening Day, here’s a look back at some recent coverage in Psychiatric Times about the diagnosis, treatment, and management of alcohol misuse.

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

What is new in research on SUDs?

“Epidemiological surveys have shown that gender gaps and alcohol consumption and alcohol-related harms are narrowing for women and men—such that alcohol is growing women’s health issue.”